B-cell antigen receptor complex-associated protein alpha chain (CD79a) (CD79A)

The B-cell antigen receptor complex-associated protein alpha chain, commonly known as CD79a or Ig-alpha, is a critical transmembrane protein that forms a heterodimer with CD79b (Ig-beta) (UniProt: P11912). This heterodimer associates with membrane-bound immunoglobulin to constitute the functional B-cell receptor (BCR) complex, which is essential for antigen recognition (NCBI Gene: 973). CD79a contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain that initiates intracellular signaling cascades upon antigen binding (PubMed: 25607555). These signaling pathways are vital for B-cell maturation, survival, and activation during an immune response. Mutations in the CD79A gene are linked to autosomal recessive agammaglobulinemia, a condition characterized by a severe deficiency in B-cell development and antibody production (Genetics Home Reference). In clinical oncology, CD79a serves as a highly specific diagnostic biomarker for B-cell lineage malignancies, including various lymphomas and leukemias (PathologyOutlines). Furthermore, it is an emerging therapeutic target for novel immunotherapies, such as CAR-T cells, designed to treat refractory B-cell cancers (PubMed: 31511311). While effective at depleting malignant cells, targeting CD79a also results in the depletion of healthy B cells, necessitating careful clinical monitoring of immune function.

Other names

CD79aIg-alphaMB-1IGASurface antigen B22

Signal transduction via immunoreceptor tyrosine-based activation motifs (ITAMs) (UniProt: P11912); targeted cell depletion via chimeric antigen receptor T-cell (CAR-T) mediated cytotoxicity (PubMed: 31511311).